Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) — Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the fourth quarter and full year ended December 31, 2025. Anika reported fourth quarter revenue of $30.6 million, flat compared to the fourth quarter of 2024. Gross margin expanded to 63%, driven...

– Successfully Closes $12M Public Offering, Strengthens Balance Sheet and Supports Anticipated U.S. Launch– Recent Peer-Reviewed Publication Demonstrates Advantages of Hybrid IVUS-OCT Imaging TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today reported financial results and provided an operational update for the fiscal quarter ended December 31, 2025 (Fiscal Q1 2026). “Conavi is approaching a key inflection point with anticipated U.S. FDA 510(k) clearance of our next-generation Novasight Hybrid™ system in the first half of 2026,” said Thomas Looby, President and Chief Executive Officer of...

Worldwide revenue of $406.8 million and $1.54 billion for the fourth quarter and full year 2025 GAAP fully diluted earnings per share of $0.82 and $3.41 for the fourth quarter and full year 2025 Adjusted fully diluted earnings per share of $1.67 and $6.08 for the fourth quarter and full year 2025 Repurchased $100 million of shares of common stock in the fourth quarter pursuant to the previously announced stock repurchase plan that was approved by the Board in July 2025 Company announced today that it is sharpening its strategic focus to innovative radiodiagnostics and pursuing value‑maximizing alternatives for radiotherapeutic assets to support long-term growth Company provides full year 2026 revenue and adjusted fully diluted earnings per share guidanceBEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc....

– Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the Second Quarter of 2026 – – Phase 1b Proof-of-Concept Trials of ATI-052 in Atopic Dermatitis (AD) and Asthma Underway; Top Line Results from Both Trials Anticipated in the Second Half of 2026 – – Investigational New Drug (IND) Application for Lead ITK Inhibitor Candidate ATI-9494 Expected in the SecondHalf of 2026 – – ATI-2138, Aclaris’ Investigational Inhibitor of ITK and JAK3, Demonstrated Potential Best-in-Class Hair Regrowth in Murine Alopecia Model – WAYNE, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS),...

$58.0 million in record quarterly revenue with Q4 exceeding the first three 2025 quarters combined  Secured over $240 million with nearly 1.1 GWh of new orders in Q4 from eight customers spanning U.S. and international markets, highlighting diversified market demand Successfully executed a $600 million senior convertible notes issuance and registered direct common stock offering, ending the year with a record cash balance of $624.6 million Current liquidity and operational funding plan support ongoing operations and substantial doubt no longer exists about Company’s ability to continue as a going concern Launched Indensity™, a next-generation architecture built with Spatial Intelligence that targets up to 1 GWh per acre while delivering industry-leading flexibility and safety Initiates 2026 revenue guidance of $300 million to...

SHELTON, Conn., Feb. 26, 2026 (GLOBE NEWSWIRE) — Acme United Corporation (NYSE American: ACU) today announced that net sales for the quarter ended December 31, 2025 were $47.5 million compared to $45.9 million in the fourth quarter of 2024, an increase of 3%. Net sales for the year ended December 31, 2025 were $196.5 million compared to $194.5 million in 2024, an increase of 1%. Net income was $1.9 million, or $0.46 per diluted share, for the quarter ended December 31, 2025 compared to $1.7 million, or $0.41 per diluted share, for the same period in 2024, an increase of 10% in net income and 12% in diluted earnings per share. Net income for the year ended December 31, 2025, was $10.2 million, or $2.49 per diluted share, compared to $10.0 million, or $2.45 per diluted share, for 2024, an increase of 2% in both net income and diluted...

ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its fourth quarter and full year results before the market open on Thursday, March 19, 2026, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day. The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13757396. The replay will be available until March 26, 2026. Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor...

 (all amounts are in U.S. dollars except where otherwise indicated)(1) Please refer to “Definition and reconciliation of non-GAAP financial measures and related ratios” in this press release  Record fourth quarter net sales from continuing operations of $1,078 million, up 31.3% vs. the prior year, including HanesBrands’ contribution since December 1, 2025 Fourth quarter operating margin of 9.2%, adjusted operating margin1 of 20.7% Fourth quarter GAAP diluted EPS from continuing operations of $0.32, down 62.8% vs. the prior year, and record fourth quarter adjusted diluted EPS1 from continuing operations of $0.96, up 15.7% vs. the prior year Cash flow from operations of $336 million in Q4, up 59.8% vs. the prior year and $606 million for the full year, an increase of 20.9% vs. the prior year; free cash flow1...

Fourth Quarter HighlightsFourth quarter sales totaled $1.49 billion, up 13.2% driven by acquisitionsCompleted SPI Acquisition Full Year HighlightsCompleted seven acquisitions, adding approximately $1.2 billion in annual salesReturned $434.2 million in capital to stockholders through the repurchase of ~1.4 million shares 2026 OutlookExpects 2026 sales between $5.925 to $6.225 billion andadjusted EBITDA in the range of $1.005 billion to $1.155 billionAcquisitions continue to be top priority for deploying capital DAYTONA BEACH, Fla., Feb. 26, 2026 (GLOBE NEWSWIRE) — TopBuild Corp. (NYSE:BLD) a leading installer of insulation and commercial roofing and a specialty distributor of insulation and related building products to the construction industry in the United States and Canada, today reported results for the fourth quarter and year...

Revenue of $678.8 million and Direct-to-Consumer (“DTC”) Revenue of $250.1 millionDTC Revenue Increased 19.5% Sequentially and 43.2% Year-Over-Year Net Loss of $(309.3) million, Adjusted Net Income of $89.0 million, and Adjusted EBITDA of $201.4 million HERZLIYA, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) — Playtika Holding Corp. (NASDAQ: PLTK) today released financial results for its fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights:Revenue of $678.8 million increased 0.6% sequentially and 4.4% year-over-year. DTC platforms revenue of $250.1 million increased 19.5% sequentially and 43.2% year-over-year. Net loss of $(309.3) million and Adjusted net income of $89.0 million. Net loss reflects a non-cash impact from contingent consideration remeasurement related to the earnout payment...